Subconjunctival Adalimumab for Noninfectious Uveitis: A Prospective Pilot Study
Subconjunctival administration of 5 mg adalimumab is a safe and effective therapy for NIU refractory to conventional IMT.
Authors
- Eleftherios I. Paschalis (ORCID: https://orcid.org/0000-0002-4544-4452)
- Soumyava Basu (ORCID: https://orcid.org/0000-0002-6513-8786)
- Thomas H. Dohlman (ORCID: https://orcid.org/0000-0002-3818-4541)
- Sucheta Ireni
- Mudit Tyagi
Institutions
- Massachusetts Eye and Ear Infirmary (US)
- Harvard University (US)
- L V Prasad Eye Institute (IN)
Publication Details
- Journal
- Ocular Immunology and Inflammation
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1080/09273948.2025.2512170
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Health Research
- Wellcome Trust
- Hyderabad Eye Research Foundation